News | Drug-Eluting Balloons | October 15, 2015

Lutonix Global Real-World Registry Outcomes Presented at TCT 2015

Peripheral arterial disease patients demonstrated freedom from target lesion revascularization rate of 94.3 percent at 12 months, 93 percent at 24 months

Lutonix Global Real-World Registry results, TCT 2015, Lutonix 035 DCB, peripheral arterial disease, PAD

Image courtesy of C.R. Bard

October 15, 2015 — C. R. Bard Inc. announced the presentation of the 12-month results from the Lutonix Global Real-World Registry at the Transcatheter Cardiovascular Therapeutics (TCT) 2015 meeting. These results come just months after publication in the New England Journal of Medicine of the one-year data from the Lutonix 035 drug coated balloon (DCB) catheter pivotal, randomized LEVANT 2 trial.

In this registry study, the Lutonix 035 DCB demonstrated a freedom from target lesion revascularization (TLR) rate of 94.3 percent in femoropopliteal arteries at 12 months in 631 patients and, based upon interim data from 170 patients (who were early enrollees), a freedom from TLR rate of 93 percent at 24 months.

Prof. Dierk Scheinert, head of Department Interventional Angiology at the University of Leipzig in Germany, commented, “The final 12-month results of the Lutonix Global Registry demonstrated how real-world PAD [peripheral arterial disease] patients with complex and long lesions can benefit from this DCB technology without leaving metal behind. Also encouraging are the interim 24-month results which suggest durable benefits of the Lutonix DCB.”

Globally, nearly 202 million patients suffer from PAD, which if untreated could lead to serious complications or even death. According to the American Heart Association, PAD affects nearly 8 million Americans with more than 50 percent of cases involving the femoropopliteal arteries in the legs. Patients with femoropopliteal PAD have reduced blood flow to their lower extremities due to narrowed arteries and carry the risk of amputations, a cause of significant physical and psychological burden to patients and substantial costs to the healthcare system.

The Lutonix 035 DCB is an angioplasty balloon coated with a therapeutic dose of the drug paclitaxel, which utilizes standard mechanical dilatation to restore blood flow for patients with de novo or restenotic lesions of up to 150mm in length in native superficial femoral or popliteal arteries.

For more information:

Related Content

Videos | TCT | November 15, 2017
DAIC Editor Dave Fornell shows some of the innovations displayed on the expo floor at the 2017 Transcatheter Cardiova
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | TCT | November 09, 2017
November 9, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has select
Key Interventional Cardiology and structural heart Technologies to Prepare for TCT 2017.
Feature | TCT | October 26, 2017 | Dave Fornell
Here is an aggregation of DAIC content for all major cardiovascular technology news and advances this past year. These...
Videos | TCT | November 18, 2016
DAIC Editor Dave Fornell takes a video tour of some of the most innovative new interventional cardiology technologies
Videos | TCT | November 05, 2015
DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies pr
Videos | TCT | November 05, 2015
Tom Watson, clinical analyst for MDBuyLine, and DAIC Dave Fornell discuss some of the technology trends at the 2015 T
Amaranth Fortitute Bioresorbable stent

The Amaranth Fortitute bioresorbable stent was among several fully bioresorbing platforms discussed in sessions, late breaking trial data presentations and on the expo floor at TCT 2015.

Feature | TCT | October 19, 2015 | Tom Watson, BS, RCVT, Clinical Analyst, MD Buyline
There were several overarching technology trends seen at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) ann
Overlay Init